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Abstract
Background: For still unclear reasons, chronic airway infection often occurs in patients with Chronic Obstructive
Pulmonary Disease (COPD), particularly in those with more severe airflow limitation. Fatty-acid binding protein
4 (FABP4) is an adipokine involved in the innate immune response against infection produced by alveolar
macrophages (Mɸ). We hypothesized that airway levels of FABP4 may be altered in COPD patients with
chronic airway infection.
Methods: In this prospective and controlled study we: (1) compared airway FABP4 levels (ELISA) in induced
sputum, bronchoalveolar lavage fluid (BALF) and plasma samples in 52 clinically stable COPD patients (65.2 ±
7.9 years, FEV1 59 ± 16% predicted) and 29 healthy volunteers (55.0 ± 12.3 years, FEV1 97 ± 16% predicted); (2)
explored their relationship with the presence of bacterial airway infection, defined by the presence of potentially
pathogenic bacteria (PPB) at ≥103 colony-forming units/ml in BALF; (3) investigated their relationship with the quantity
and proportion of Mɸ in BALF (flow cytometry); and, (4) studied their relationship with the severity of airflow limitation
(FEV1), GOLD grade and level of symptoms (CAT questionnaire).
Results: We found that: (1) airway levels of FABP4 (but not plasma ones) were reduced in COPD patients vs. controls
[219.2 (96.0–319.6) vs. 273.4 (203.1–426.7) (pg/ml)/protein, p = 0.03 in BALF]; (2) COPD patients with airway infection
had lower sputum FABP4 levels [0.73 (0.35–15.3) vs. 15.6 (2.0–29.4) ng/ml, p = 0.02]; (3) in COPD patients, the number
and proportion of Mɸ were positively related with FABP4 levels in BALF; (4) BALF and sputum FABP4 levels were
positively related with FEV1, negatively with the CAT score, and lowest in GOLD grade D patients.
Conclusions: Airway FABP4 levels are reduced in COPD patients, especially in those with airway infection and more
severe disease. The relationship observed between Mɸ and airway FABP4 levels supports a role for FABP4 in the
pathogenesis of airway infection and disease severity in COPD.
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) cur-
rently is the third leading cause of mortality worldwide
[1]. Chronic airway bacterial infection often occurs in
COPD patients, particularly in those with more severe
airflow limitation [2, 3]. The presence of airway infection
increases the economic impact of the disease and
worsens clinical outcomes including increased mortality
[4]. Several studies have demonstrated that innate im-
munity alterations favor airway infection in COPD [5, 6].
However, the underlying biological mechanisms leading
to chronic airway infection in COPD have not been yet
fully elucidated.
Alveolar macrophages (Mɸ) are a central component
of the innate immune response against airway infection.
Several alterations of Mɸ in marker expression and func-
tions have been previously described in COPD [7, 8].
Among many other functions, Mɸ produce fatty acid-
binding protein 4 (FABP4), also known as adipocyte A-
FABP or aP2. FABP4 is a member of the FABP family of
small-molecular weight intracellular lipid chaperones that
functions as a secreted adipokine and plays a role in air-
way defense against infection [9, 10]. For instance, in an
experimental model of Pseudomonas aeruginosa infection
in mice, the presence of FABP4 protected against airway
infection [11]. However, limited data on COPD and its re-
lationship with disease severity and airway infections are
available.
We hypothesized that airway FABP4 levels may be re-
duced in COPD patients, especially in those with the more
severe disease and with potentially more dysfunctional
Mɸ. Accordingly, this study sought to: (1) compare airway
(and plasma) FABP4 levels in COPD and healthy volun-
teers and, (2) study their relationship with presence of air-
way infection, quantity and proportion of Mɸ and several
clinical markers of disease severity, such as the severity of
airflow limitation (FEV1), the GOLD classification and the
level of symptoms (CAT questionnaire).
Methods
Study design and ethics
This was a prospective, multicenter, cross-sectional
study that included clinically stable COPD patients and
healthy volunteers with normal lung function, who
served as controls. Participants were recruited from five
university tertiary hospitals [Hospital de la Santa Creu i
Sant Pau (Barcelona, Spain), Hospital del Mar (Barce-
lona, Spain), Hospital Universitari Parc Taulí (Sabadell,
Spain), Hospital Germans Trias i Pujol (Barcelona,
Spain) and Hospital Clínic (Barcelona Spain)]. The study
protocol was approved by the local institutional review
board (IIBSP-MIC-2015-57) and all subjects gave signed
informed consent.
Participants
The diagnosis of COPD was established according to the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) guidelines [12]. The inclusion criteria were: 8
weeks of clinical stability (defined by the absence of an
exacerbation that required oral corticosteroids and/or
antibiotic treatment), age between 40 and 75 years, and
FEV1 between 20 and 70% predicted. All patients under-
went a computerized tomography scan, and those with
bronchiectasis, lung cancer, pneumonia, and/or intersti-
tial lung diseases were excluded. Other exclusion criteria
were patients with active malignant disease and/or any
type of immunosuppression, drug addiction or alcohol
abuse. As controls, we included adult volunteers without
respiratory diseases and with normal spirometry re-
cruited in these same centers [13].
Clinical assessment
Demographic data, the number of exacerbations in the
previous year, the time from last exacerbation, relevant
comorbid conditions and current treatments were re-
corded at inclusion using standardized questionnaires. All
patients underwent spirometry (Datospir-600; Sibelmed
SA, Barcelona, Spain) following international recommen-
dations. Reference values were those of Mediterranean
populations [14].
Samples collection and processing
Bronchoalveolar lavage fluid (BALF), induced sputum
and plasma were obtained from all participants and were
processed immediately. BALF samples were recovered
using 150 ml saline lavage with the bronchoscope
wedged in the right middle lobe. BALF samples were
centrifuged at 800 xg for 10 min to obtain the cellular
pellet and the supernatant. Induced sputum was col-
lected just before the bronchoscopy as previously de-
scribed [15]. Sputum samples were disaggregated using
dithiothreitol (Oxoid Ltd., Hampshire, United Kingdom)
for 15min and were centrifuged at 600 xg for 6min to ob-
tain the supernatant. Proteases inhibitors (Calbiochem,
San Diego, CA) were added to the supernatants during
thawing. Plasma samples were obtained from blood col-
lected in ethylenediamine tetra-acetic acid (EDTA) tube
and centrifuged at 850 xg for 10min. BALF and sputum
supernatants and plasma were stored immediately at −
80 °C until analysis.
Microbiological study
Samples were processed for qualitative and quantitative
bacteriology, as previously described [16]. Airway infec-
tion was defined as the presence of potentially patho-
genic bacteria (PPB) at ≥103 colony-forming units/ml in
BALF [17] in clinically stable patients.
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FABP4 measurement
FABP4 levels were measured by validated, commercially
available ELISA kit (RayBiotech, Peachtree Corners, GA)
according to the manufacturer’s instructions. The limit
of kit detection was 38 pg/ml. The dilutions used were
1/7 for BALF supernatants, 1/5 for sputum supernatants
and 1/75 for plasma. BALF FABP4 levels were adjusted
to the total protein content quantified using Qubit
fluorometer (Invitrogen, Carlsbad, CA).
BALF flow cytometry
In COPD patients, cellular pellet obtained from BALF
samples was lysed to avoid red blood cells contamin-
ation (RBC lysing solution; BioLegend, San Diego, CA).
Cells were resuspended in one ml of PBS supplemented
with 2% bovine serum albumin (BSA; Roche Diagnostics
GmbH, Mannheim, Germany) to quantify the number of
total cells in a MACSQuant cytometer (Miltenyi Biotec,
Bergisch Gladbach, Germany). Cells were adjusted to
1x106cells/ml and stained for 15min at room temperature
in dark with viability dye (Zombie NIR; BioLegend), CD45-
FITC, CD14-APC (Immunotools GmbH, Friesoythe,
Germany) and CD15-PE (Biolegend, San Diego, CA).
Aggregated and non-viable cells were excluded from the
analysis. Mɸ were gated according to CD45 positive popu-
lation, CD15 negative, CD14 positive and high side scatter
(SSC) parameter.
Statistical analyses
Results of continuous variables are presented as mean
and standard deviation (SD) or median and interquartile
range [25th – 75th percentile IQR], according to the
Kolmogorov-Smirnov test of normality distribution,
whereas categorical variables are presented as frequen-
cies. Groups were compared using Student t-test,
ANOVA test or their corresponding non-parametrical
test when required. Correlations were analyzed using
Spearman’s Rho due to the variables did not present a
normal distribution. A p-value < 0.05 was considered sig-
nificant. Statistical analyses were performed using SPSS
version 22 and Graph Pad Prism 7 software.
Results
Characteristics of participants
Fifty-two COPD patients and 29 controls were included.
Table 1 shows their demographic and clinical character-
istics. COPD patients were older (65.2 ± 7.9 vs. 55.0 ±
12.3, p = 0.0002) than controls but gender (75.9 vs.
65.4% males, p = 0.6) and BMI (26.3 ± 4.7 vs. 28.7 ± 9.7,
p = 0.7) were similar in both groups. Airflow limitation
in patients with COPD ranged from mild to severe
(FEV1 of 59 ± 15% of predicted) whereas spirometry was
normal in controls by design. Twenty-four patients
(46%) were classified as GOLD grade C and D, and 21
patients (40%) were frequent exacerbators, defined as
those patients who suffered from 2 or more exacerba-
tions during the previous year to the inclusion.
Twelve COPD patients (23%) had airway infection.
Patients with airway infection were predominantly males
(92%) and older than non-infected ones (Table 2).
Haemophilus influenzae was the most common PPB iso-
lated (n = 9, 75%), followed by Streptococcus pneumoniae
(n = 2, 17%) and Moraxella catharralis (n = 1, 8%).
Airway and systemic FABP4 levels in patients and
controls
Airway FABP4 levels were lower in COPD patients than
in controls, reaching statistical significant differences in
BALF [219.2 (96.0–319.6) vs. 273.4 (203.1–426.7) (pg/
ml)/protein, p = 0.03], but not in sputum [12.2 (0.7–
27.5) vs. 14.5 (0.5–45.6) ng/ml, p = 0.4] (Fig. 1A, C). Yet,
we observed a positive significant correlation between
BALF and sputum FABP4 levels in the entire population
(rho = 0.31, p = 0.01) and in COPD patients (rho = 0.37,
p = 0.01). On the other hand, plasma FABP4 levels were
similar in patients and controls [26.6 (19.3–39.5) vs. 25.2
(18.3–36.5) ng/ml, p = 0.4)] and no significant correl-
ation was observed between systemic and airway FABP4
levels.
FABP4 levels and airway infection in COPD patients
Airway FABP4 levels were lower in COPD patients with
airway infection vs. those without it, reaching statistical
significant differences in sputum [0.73 (0.35–15.3) vs.
15.6 (2.0–29.4) ng/ml, p = 0.02] but not in BALF [181.5
(28.7–395.5) vs. 228.5 (106.3–319.1) (pg/ml)/protein,
p = 0.7) (Fig. 1B, D). No differences in plasma FABP4
levels were observed between COPD patients with and
without airway infection [29.8 (20.4–45.0) vs. 26.1 (19.3–
37.9) ng/ml, p = 0.6].
Table 1 Demographics and clinical characteristics among
controls and COPD patients
Controls (n = 29) COPD (n = 52) P value
Age 55.0 ± 12.3 65.2 ± 7.9 0.0002
Male, n (%) 22 (75.9) 34 (65.4) 0.6
BMI (kg/m2) 28.7 ± 9.7 26.3 ± 4.7 0.7
Smoking status, n (%)
Never 5 (17.2) 0 (0.0) < 0.0001
Former 10 (34.5) 41 (78.8)
Current 14 (48.3) 11 (21.1)
Pack-years 26.0 ± 19.0 43.5 ± 19.2 0.002
FEV1 (% pred) 97 ± 16 59 ± 16 < 0.0001
FVC (% pred) 92 ± 15 85 ± 16 0.07
FEV1/FVC 0.79 ± 0.05 0.52 ± 0.14 < 0.0001
Data is presented as mean ± SD unless otherwise indicated
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FABP4 levels and disease severity
Airway (but not plasma) FABP4 levels were related with
several measures of disease severity, including GOLD
stage, airway limitation and quality of life. Patient with
GOLD D had the lowest values both in BALF (Fig. 2A)
and sputum (Fig. 2B). In addition, a positive correlation
among airway FABP4 levels and FEV1 (% predicted)
(Fig. 3A, B) and a negative correlation with levels of
symptoms measured in CAT questionnaire (Fig. 3C, D)
were observed.
No differences in airway FABP4 levels were observed
regarding age and smoking status. Patients using inhaled
corticosteroid (ICS) had lower values in BAL compared
with those without ICS [(pg/ml)/protein, 123.6 (12.6–
306.4) vs 250 (171.6–344.7), p = 0.03)].
FABP4 and alveolar Mɸ
Alveolar Mɸ represented 49.9 (26.4–76.8) % of cells in
BALF of COPD patients, corresponding to an absolute
number of 140 (48.9–311) Mɸ per μl. Both proportion and
absolute number of alveolar Mɸ were significantly related
with BALF FABP4 levels [proportion (rho = 0.54, p =
0.0003) and absolute number (rho = 0.52, p = 0.0006)]
(Fig. 4). No significant differences among infected and non-
infected patients and related to GOLD stage were found.
Discussion
The main results of this study show that, as hypothe-
sized: (1) airway (but not plasma) levels of FABP4 are re-
duced in COPD patients, particularly in those with
airway infection and more severe disease; and, (2) BALF
Table 2 Patient demographics, clinical characteristics and prior treatments among non-infected and infected patients
Non-infected (n = 40) Infected (n = 12) P value
Age 63.7 ± 7.6 69.9 ± 6.9 0.02
Male, n (%) 23 (57.5) 11 (91.7) 0.04
Smoking status, n (%)
Never 0 (0) 0 (0) 0.7
Former 31 (77.5) 10 (83.3)
Current 9 (22.5) 2 (16.7)
Pack-years 42.3 ± 20.0 47.8 ± 16.1 0.2
Comorbid conditions, n (%)
Cardiovascular 13 (32.5) 6 (50) 0.3
Hypertension 15 (37.5) 6 (50) 0.4
Diabetes 0 (0) 0 (0) 1
Gastroesophageal reflux 14 (35) 6 (50) 0.3
Treatment, n (%)
ICS 22 (55) 6 (50) 0.5
LABA 32 (80) 8 (66.7) 0.3
LAMA 32 (80) 11 (91.7) 0.3
FEV1 (% pred) 58 ± 169 61 ± 17 0.6
FVC (% pred) 87 ± 16 76 ± 17 0.04
BMI (kg/m2) 26.4 ± 4.8 26.0 ± 4.4 0.8
GOLD stage, n (%)
A 13 (32.5) 6 (50) 0.4
B 8 (20) 1 (8.3)
C 9 (22.5) 1 (8.3)
D 10 (25) 4 (33.4)
Prior exacerbations, n (%)
0 16 (40) 4 (33.3) 0.9
1 8 (20) 3 (25)
≥ 2 16 (40) 5 (41.7)
Weeks from last exacerbation 26.2 ± 18.9 27.3 ± 19.1 0.6
CAT questionnaire 11.2 ± 6.5 10.5 ± 7.6 0.6
Data is presented as mean ± SD unless otherwise indicated
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Fig. 1 Airway FABP4 levels in COPD. A BALF FABP4 levels in controls and COPD patients and (B) in non-infected and infected patients. C Sputum
FABP4 levels in controls and COPD patients and (D) in non-infected and infected patients. P-values were obtained by Mann-Whitney test. *p-
value < 0.05. Data is represented as median with interquartile range
Fig. 2 Association of airway FABP4 levels and disease severity. A BALF and (B) Sputum FABP4 levels and GOLD stages classified in mild (GOLD A),
moderate (GOLD B), severe (GOLD C) and very severe (GOLD D). P-values were obtained by Mann-Whitney test. *p-value < 0.05 and
**p-value < 0.01. Data is represented as median with interquartile range
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FABP4 levels are related to the number and proportion
of alveolar Mɸ. Collectively, these results suggest that re-
duced production of FABP4 by alveolar Mɸ is associated
with the presence of airway infection in COPD.
Previous studies
FABP4 is an adipokine widely studied in metabolic
and cardiovascular diseases [18]. Its role in chronic
respiratory diseases is poorly understood, although it
has been recognized that FABP4 is associated with
airway inflammation [19]. Likewise, a dysregulation of
airway FABP4 has been previously described in
asthma [20] where it has been shown in experimental
models that FABP4 participates in the recruitment
and activation of eosinophils [21]. In patients with
COPD, a dysregulation of systemic FABP4 compared
with controls has been suggested [22], which is at
variance with our findings here. Differences may be
related to distinct inclusion criteria. Whereas Zhang
et al excluded patients with metabolic and vascular
Fig. 3 Relationship between FEV1 and (A) BALF FABP4 and (B) sputum FABP4. Relationship between CAT score and (C) BALF FABP4 and (D)
sputum FABP4. Data was obtained using Spearman correlation
Fig. 4 Relationship between BALF FABP4 levels and (A) proportion and (B) absolute number of BALF Mɸ. Data was obtained using Spearman correlation
Perea et al. Respiratory Research           (2020) 21:21 Page 6 of 8
comorbidities [22], known to be associated with ele-
vated systemic FABP4 levels [23, 24], we did not
because cardiovascular comorbidities are highly preva-
lent in patients with COPD (74% in our cohort) and
we did not want to bias our study population. In any
case, to our knowledge, our study is the first to inves-
tigate airway FABP4 levels, and their relationship with
airway infection and disease severity in COPD.
Interpretation of novel findings
Bacterial airway infections are relevant in the natural his-
tory of COPD [3] because it worsens clinical outcomes, in-
cluding mortality and costs [4]. The molecular and
cellular mechanisms that favor bacterial infection in some
COPD patients are, however, not yet fully elucidated. We
observed that airway FABP4 levels were reduced in COPD
patients, particularly in those with evidence of airway in-
fection, and we found a relationship between BALF Mɸ
(absolute number and proportion) and FABP4 levels in
COPD. Given that alveolar Mɸ produce FABP4 [9], these
observations support a pathogenic role for a locally defect-
ive Mɸ production of FABP4. In support of this interpret-
ation is the fact that FABP4 facilitates the interaction
between Mɸ and neutrophils through the regulation of
CXCL1, a chemokine secreted by Mɸ to recruit neutro-
phils to the site of infection [11, 25]. Further works study-
ing Mɸ subpopulations would help to better understand
the immunological mechanism related to FABP4 produc-
tion by Mɸ.
On the other hand, we found that patients with severe
COPD showed the lowest airway FABP4 levels. We also
found that there was a direct relationship between
airway FABP4 concentration and FEV1 levels and an in-
verse relationship between the former and CAT score
(i.e. worse health status). In keeping with these observa-
tions, some previous studies had demonstrated that pa-
tients with severe COPD have altered airway innate
immunity [16, 26, 27] that leads to chronic airway in-
flammation and dysregulation of normal alveolar Mɸ
function [28]. Yet, because our study is cross-sectional,
we cannot infer what is the cause and what is the conse-
quence, this is, what comes first.
Potential limitations
Our study has some limitations that deserve comment.
First, controls were younger than COPD patients, but
we did not observe any relationship between airway
FABP4 levels and the age of the participants. Second, in-
duced sputum was collected just before the bronchos-
copy so we cannot discard any interaction with BALF
samples, although this procedure had been applied to all
the participants. Third, we did not perform flow cytome-
try in BALF from controls, but it is well reported in the
literature that COPD alveolar Mɸ differ from healthy
controls in phenotype [29] and in the ability to phago-
cytose bacteria and apoptotic cells [30, 31]. Forth, we
have not determined FABP4 in infected patients without
COPD and it would be of great interest to better under-
stand its role in the pathogenesis or airway infection.
Finally, we did not obtain follow-up samples, so we can-
not infer if any therapeutic intervention (e.g., treatment
with low dose azithromycin) can restore airway FABP4
levels and what clinical consequences that may have.
Conclusions
FABP4 airway levels (but not plasma ones) are reduced
in COPD patients, especially in those with chronic air-
way infection and more severe disease, in relation to a
reduced number of alveolar Mɸ. These observations
may be relevant for a better understanding of the patho-
genesis (and eventual prevention or treatment) of
chronic airway infection in these patients.
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